ArticleAndrology2026
Smooth Muscle Cell-Derived Exosomal miR-30a-5p as a Novel Therapeutic Strategy for Erectile Dysfunction in Diabetes Mellitus.
Article in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles in erectile dysfunction: a narrative review of multicellular regulation.Translational andrology and urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundErectile dysfunction (ED) affects more than half of male patients with diabetes. Diabetes mellitus-related ED (DMED) remains challenging to manage due to hyperglycemia-induced apoptosis and fibrosis of corpus cavernosum smooth muscle cells (SMCs). Exosomes secreted by normal SMCs (NSMC-EXOs) have emerged as promising therapeutic vectors. This study investigated the therapeutic role and molecular mechanism of NSMC-EXO-carried microRNA-30a-5p (miR-30a-5p) in DMED.
methodsErectile function in DMED rats treated with NSMC-EXOs was assessed via electrophysiological testing. Exosomal miRNA profiles were characterized by sequencing, and potential target genes were identified through bioinformatic prediction. The interaction between miR-30a-5p and Calm1 was experimentally validated. Expression levels of miR-30a-5p, Calm1, and markers of apoptosis and fibrosis were examined in vivo and in vitro. MiR-30a-5p mimics and inhibitors were employed to confirm the regulatory mechanism.
resultsAdministration of NSMC-EXOs significantly restored erectile function in DMED rats. Sequencing revealed a marked enrichment of miR-30a-5p in NSMC-EXOs compared with exosomes from high-glucose-treated SMCs. Calm1 was identified as a direct target of miR-30a-5p, with involvement in apoptotic and fibrotic signaling pathways. Both in vivo and in vitro studies demonstrated that NSMC-EXO-derived miR-30a-5p was efficiently internalized by SMCs, suppressed Calm1 expression, and inhibited activation of the Calm1-AMPK-JNK and Calm1-CaMK2-TGFβ1 cascades. Consequently, apoptosis and fibrosis of corpus cavernosum tissue under hyperglycemic conditions were alleviated. Importantly, these protective effects were abolished following miR-30a-5p inhibition, underscoring its pivotal role.
conclusionNSMC-EXO-derived miR-30a-5p protects against DMED by directly targeting Calm1 and attenuating pro-apoptotic and pro-fibrotic signaling. These findings provide mechanistic insight supporting the development of exosome-based therapeutic approaches for DMED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.